Literature DB >> 16824023

The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense.

Arman A Bashirova1, Maureen P Martin, Daniel W McVicar, Mary Carrington.   

Abstract

Killer immunoglobulin-like receptors (KIRs) are molecules expressed on the surface of natural killer (NK) cells, which play an important role in innate immunity. KIR recognition of major histocompatability complex (MHC) class I allotypes represents one component of the complex interactions between NK cells and their targets in determining NK cell reactivity. KIRs are encoded by a gene cluster at human chromosome 19q13.4. Despite their high degree of sequence identity, KIR genes encode proteins that have diverse recognition patterns (specific HLA class I allotypes) and confer opposing signals (activating or inhibitory) to the NK cell. The KIR gene cluster is highly polymorphic, with individual genes exhibiting allelic variability and individual haplotypes differing in gene content. The polymorphism of the KIR locus parallels that of the MHC, facilitating the adaptation of the immune system to a dynamic, challenging environment. This variation is associated with a growing number of human diseases, which is likely to extend to levels observed for the HLA loci. Here we review current progress in understanding KIR biology and genetics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16824023     DOI: 10.1146/annurev.genom.7.080505.115726

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  122 in total

1.  Killer cell immunoglobulin-like receptors (KIR) typing by DNA sequencing.

Authors:  Lihua Hou; Minghua Chen; Noriko Steiner; Kanthi Kariyawasam; Jennifer Ng; Carolyn K Hurley
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Innate immune control of HIV.

Authors:  Mary Carrington; Galit Alter
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.

Authors:  Susan E Hiby; Richard Apps; Andrew M Sharkey; Lydia E Farrell; Lucy Gardner; Arend Mulder; Frans H Claas; James J Walker; Christopher W Redman; Christopher C Redman; Linda Morgan; Clare Tower; Lesley Regan; Gudrun E Moore; Mary Carrington; Ashley Moffett
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

Review 4.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

5.  Another earth: innate lymphoid cells and intestinal inflammation.

Authors:  Lin Lin; Jonathan Braun
Journal:  Gastroenterology       Date:  2011-09-28       Impact factor: 22.682

6.  HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial.

Authors:  Heather A Prentice; Philip K Ehrenberg; Karen M Baldwin; Aviva Geretz; Charla Andrews; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Robert J O'Connell; Merlin L Robb; Jerome H Kim; Nelson L Michael; Rasmi Thomas
Journal:  Immunogenetics       Date:  2014-03-29       Impact factor: 2.846

7.  Association of killer cell immunoglobulin-like receptor gene 2DL1 and its HLA-C2 ligand with family history of cancer in oral squamous cell carcinoma.

Authors:  Anupam Dutta; Nabajyoti Saikia; Jyotirmoy Phookan; Munindra Narayan Baruah; Shashi Baruah
Journal:  Immunogenetics       Date:  2014-05-13       Impact factor: 2.846

8.  Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Authors:  Wei Wang; Amy K Erbe; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; Jonathan M Weiss; James Mier; David Panka; David F McDermott; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-09-30       Impact factor: 6.968

9.  Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa.

Authors:  Neda Nemat-Gorgani; Hugo G Hilton; Brenna M Henn; Meng Lin; Christopher R Gignoux; Justin W Myrick; Cedric J Werely; Julie M Granka; Marlo Möller; Eileen G Hoal; Makoto Yawata; Nobuyo Yawata; Lies Boelen; Becca Asquith; Peter Parham; Paul J Norman
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

Review 10.  KIRigami: the case for studying NK cell receptors in SIV+ macaques.

Authors:  Benjamin Bimber; David H O'Connor
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.